The Coordinated Action aims to facilitate the establishment of collaborative projects, strengthen R&D and propose new diagnostic, therapeutic and vaccine approaches in response to major issues related to tuberculosis.
Last updated on 16 April 2024
With 10.6 million cases and approximately 1.3 deaths worldwide in 2022 (WHO, November 2023), which makes it the second leading cause of death from a single infectious agent, tuberculosis remains a major public health problem. The aim of this Coordinated Action is to reduce this mortality.
Its objectives include:
This Coordinated Action is tasked with:
Key words: Tuberculosis, Mycobacterium tuberculosis, pathophysiology, host-pathogen interaction, prevention, vaccine, diagnosis, treatment, mortality, public health, basic research, clinical research, extra-pulmonary tuberculosis, latent tuberculosis, treatment resistance, host-targeted therapies, TB-HIV co-infection, immunodepression, pregnant women, children, adolescents, persistence, correlates of protection.
The coordinated action on Tuberculosis is structured around three cross-disciplinary workgroups (WGs) covering the pathophysiology of the disease (pathogen biology, host immune response, host-pathogen interactions), prevention, diagnosis, treatment and public health:
Olivier Neyrolles
IPBS, CNRS, Toulouse
François-Xavier Blanc
Nantes University, University Hospital, Nantes
Alain Baulard
(Lille Infection and Immunity Centre, Institut Pasteur de Lille)
Guislaine Carcelain
(Robert Debré Hospital, Paris)
Didier Laureillard
(University Hospital, Nîmes)
Olivier Marcy
(IRD EMR271, Bordeaux University)
Cécile Peltékian
(Department of Basic Research, ANRS MIE)
Guia Carrara
(Department of Basic Research, ANRS MIE)
Maimouna Djamila Ngadjaga (Department of Basic Research, ANRS MIE)
Maryline Bonnet
(IRD, Montpellier)
Nathalie De Castro
(Saint-Louis Hospital, Paris)
Philippe Van De Perre (UMR Pathogenesis and control of chronic and emerging infections, Montpellier)